Prioritizing symptom management in the treatment of chronic heart failure

Aaron O. Koshy1†, Elisha R. Gallivan1†, Melanie McGinlay2, Sam Straw1, Michael Drozd1, Anet G. Toms2, John Gierula1, Richard M. Cubbon1, Mark T. Kearney1 and Klaus K. Witte1*

1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Clarendon Way, Leeds, LS2 9NL, UK; 2Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Abstract

Chronic heart failure (CHF) is a chronic, progressive disease that has detrimental consequences on a patient’s quality of life (QoL). In part due to requirements for market access and licensing, the assessment of current and future treatments focuses on reducing mortality and hospitalizations. Few drugs are available principally for their symptomatic effect despite the fact that most patients’ symptoms persist or worsen over time and an acceptance that the survival gains of modern therapies are mitigated by poorly controlled symptoms. Additional contributors to the failure to focus on symptoms could be the result of under-reporting of symptoms by patients and carers and a reliance on insensitive symptomatic categories in which patients frequently remain despite additional therapies. Hence, formal symptom assessment tools, such as questionnaires, can be useful prompts to encourage more fidelity and reproducibility in the assessment of symptoms. This scoping review explores for the first time the assessment options and management of common symptoms in CHF with a focus on patient-reported outcome tools. The integration of patient-reported outcomes for symptom assessment into the routine of a CHF clinic could improve the monitoring of disease progression and QoL, especially following changes in treatment or intervention with a targeted symptom approach expected to improve QoL and patient outcomes.

Keywords  Chronic heart failure; Symptom assessment; Quality of life; Patient-reported outcomes

Introduction

Chronic heart failure (CHF) is a progressive, debilitating disease characterized by persistently reduced exercise capacity and acute exacerbations that lead to repeated hospital admissions.1 More than 26 million people are estimated to be living with CHF worldwide, with a prevalence of ~1–2% in Europe.2 A globally ageing population is likely to increase these figures, increasing financial and resource pressures within healthcare systems.2,3 Guideline-approved treatments mostly focus on reducing mortality and hospitalization and preventing progressive adverse cardiac remodelling.4,5 Despite optimal medical management and device therapy, patients often have persistent symptoms and long-term reductions in quality of life (QoL)5–7 as evidenced in 400 CHF patients with serial assessments from our own published data (Figure 1)8 in which a significant portion continues to have symptoms despite optimal therapy, and over 50% of those in New York Heart Association (NYHA) Class II patients do not improve. Allen et al.9 obtained similar findings using the American PINNACLE Registry in which the trend was towards worsening symptoms rather than a reduction over 2 years of follow-up. While dyspnoea, fatigue, and oedema are classed as hallmark symptoms, pain, low mood, and chronic cough are also commonly reported by patients.10 These symptoms significantly impose on QoL and energy levels11 and are generally the reason for referral to specialist care. The symptom burden for CHF patients has been likened to those with advanced cancer or acquired immune deficiency syndrome,6,12 yet in the months prior to death, cancer

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
patients receive more frequent palliative care consultations and symptom-directed prescriptions and report a lower impact of symptoms than those with CHF.\textsuperscript{13} Even mild symptoms of CHF can directly worsen patients’ ability to manage daily activities including self-care and adherence to recommended treatment.\textsuperscript{14} As symptoms worsen, many CHF patients become dependent on carers, which adversely affects their sense of identity and will to live.\textsuperscript{6,15} The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial\textsuperscript{16} interviewed 287 patients from initial hospitalization until 6 months of post-admission revealing that shortly after discharge, more than half were willing to trade survival time for improved symptom control, but once their symptoms had stabilized beyond 6 months, the majority (68\%) prioritized survival. Factors associated with willingness to trade time included symptom severity and a higher depression score within the Minnesota Living with Heart Failure Questionnaire (MLHFQ). These data are not the only to suggest that as CHF progresses, patients are increasingly willing to trade time for symptom control.\textsuperscript{17} Symptom control is also of economic relevance. The cost of care of patients with CHF is overwhelmingly due to hospitalization,\textsuperscript{18,19} and this is largely for symptom control. Prioritizing symptom management in clinics could reduce hospital readmissions and reduce the costs of care.\textsuperscript{1,20} There are in fact many treatments proven to improve symptoms, but they are infrequently employed because of a neutral (or negative) effect on disease progression including diuretics, dobutamine, and morphine.\textsuperscript{21} We propose that a shift in focus in clinical care and research towards symptom assessment and targeted management could improve QoL and quality of life years while also being highly cost-effective and that new treatments should be assessed and considered for approval based upon their effect on symptoms rather than simply survival. However, such a shift in priority will depend upon reliable, sensitive, and reproducible assessments of both classical and atypical symptoms of CHF. Hence, in this article, we discuss the common and less common symptoms of CHF and review the tools currently available for their assessment with the aim of prompting a greater focus on symptoms.

## Methods

For this scoping review, we undertook a protocolized PubMed search to identify articles published from 1946 to October 2019 including the following search terms: Heart failure, CHF, symptoms, relief, treatment, management, quality of life, QoL, oedema, edema, swelling, fluid, fatigue, weak, cough, dyspnoea, short of breath, breathlessness, SoB, depression, mood, exercise intolerance, exercise capacity, exercise testing, patient reported outcomes, and PRO. Grey literature was also searched using Google Search and Google Scholar. The abstracts of these articles were reviewed and considered for inclusion by the two first authors (AOK and ERG) based upon the relevance of the symptom, the description, practicality of the assessment tool, method of assessment, and the interventions for which it had been applied. This article summarizes our findings: first discussing each of the common complaints found in CHF with basic pathophysiology and then examples of how these can be assessed. Table 1 provides an overview of the validated symptom assessment tools in the context of CHF. We considered a tool as validated if proven reliable against the gold standard or if there is a published test–retest reliability coefficient (or Cronbach’s alpha) greater than 0.7. Finally, where we discuss QoL, this is in the context of health and specifically to heart failure unless stated otherwise.
| Symptom assessed | Name of assessment tool with validation reference | Description | Structure | Strengths | Limitations |
|------------------|-------------------------------------------------|-------------|-----------|-----------|-------------|
| Fatigue          | Dutch Exertion Fatigue Scale\(^{22}\)          | Assesses exertional fatigue | 9-item questionnaire with participants grading across 5 responses from 0 (no) to 4 (yes) | Simple to use, Able to assess exertional fatigue, Translated in four languages | Limited utilization outside of Dutch speaking counties |
|                  | Dutch Fatigue Scale\(^{22}\)                  | Assesses general fatigue | 9-item questionnaire with responses graded from 1 to 5 on a Likert scale. This is aggregated to produce a total score ranging from 9 to 45, indicating increased fatigue. | Simple to use | Limited utilization outside of Dutch speaking counties despite translation available in four languages |
| Fatigue and      | Dyspnoea-Fatigue Index\(^{3,23}\)             | Assessed the magnitude of fatigue or dyspnoea | Three component questions scored from 0 to 4 based on the magnitude of the task that produces fatigue or dyspnoea. The score is aggregated from 0 (worst) to 12 (best). | Simple to use | Should not be used if other physical or cognitive factors can affect task, effort, or function |
| Dyspnoea         | BDI and TDI\(^{b,24}\)                        | Assesses dyspnoea in relation to ADL | BDI is developed from cumulative scores given by patients who assign a grade of 0–4 (0 = significant impairment; 4 = no impairment) for various tasks. TDI is used in tandem with TDI to track changes in dyspnoea | Determines what degree of activity provokes dyspnoea | Questions are not standardized, making the instrument user dependent resulting in potential interviewer bias. |
|                  | Dyspnoea-12\(^{25}\)                         | Assesses the patient’s perceptions and extent of dyspnoea experienced | Dyspnoea is rated ‘none’ to ‘severe’ across 12 potential associations of the symptom such as a sensation of exhaustion or distress. | Easy to use, Patient specific, Assesses multiple components of dyspnoea | The tool is not recommended if more than three questions are left unanswered, Unclear link between psychological distress and perceived breathlessness severity, Inter-operator variability |
|                  | New York Heart Association functional classification\(^{c,26}\) | Assesses limitations in physical activity manifesting as dyspnoea | Graded from 1 (no dyspnoea at strenuous exertion) to 4 (symptoms at rest) | Easy to use, Internationally recognized, Associated with prognosis, Validated extended versions, Well validated across cardiac patients |_lengthy |
| Low mood         | Beck Depression Inventory\(^{27}\)             | Assesses patient for depressive symptoms | 21-item assessment scoring depressive symptoms from 0 to 3 | Well validated across age groups and languages as repeatable and responsive, Concise and self-administered | Potential variance in different ethnic groups |
|                  | Cardiac Depression Scale\(^{28}\)             | Assesses depressed mood in cardiac patients | 26-item assessment requiring a response from 1 (strongly disagree) to 7 (strongly agree) | Well validated across age groups and languages as repeatable and responsive, Concise and self-administered | Potential variance in different ethnic groups |
|                  | Geriatric Depression Scale-Short form\(^{28}\) | Assesses patient for depressive symptoms | 15-item self-assessment scale consisting of yes/no questions | Well validated across age groups and languages as repeatable and responsive, Concise and self-administered | Potential variance in different ethnic groups |

(Continues)
Exercise intolerance

Exercise intolerance is the inability to conduct physical exertion at a ‘normal’ level and is by far the most common symptom of CHF.7 The degree of reduction in exercise capacity relates to both worse prognosis and QoL.31 Exercise intolerance is due to a combination of central factors such as heart rate and stroke volume as well as peripheral factors including skeletal muscle structure and function (Figure 2),32–34 manifesting as fatigue or dyspnoea. Exercise capacity can be determined relatively consistently in clinics using semi-quantitative and objective methods including the NYHA functional classification, the 6 min walk test, and cardiopulmonary exercise testing.35 Measures of exercise capacity outperform echocardiography in prognostic assessment.36 Furthermore, relatively small improvements in exercise time are associated with a lower hospitalization rate, superior QoL, and improved survival in the long term.37 The low sensitivity of NYHA classification and 6 min walk test limits their ability to measure change over time, while the additional equipment to measure metabolic gas exchange limits the widespread applicability of cardiopulmonary exercise testing.38,39 We prefer a simpler measure of direct patient relevance—exercise time on a treadmill or cycle—which has high reproducibility and can easily be converted to distance.40 Exercise capacity is a common endpoint for interventions in CHF. A number of treatments ranging from pharmacological such as intravenous iron, device therapies such as cardiac resynchronization therapy, and non-pharmacological options such aerobic exercise are associated with improved exercise capacity.41–43 Standardized and simplified assessment of exercise capacity could allow for a more nuanced approach to the management of symptoms, enabling patients to have greater control of functional capacity and mortality.

Fatigue

Fatigue is a hallmark symptom of CHF that affects ~85% of CHF patients.10 The origin is likely to stem from both skeletal muscles and central nervous system. It has been suggested, for example, that decreased cardiac output especially during activity leads to a greater oxygen or metabolic debt that lengthens recovery time possibly even to beyond the next activity.44 However, fatigue could also be due to sleep disturbance due to anxiety, pain, orthopnoea, or paroxysmal nocturnal dyspnoea.1,10,45 Fatigue is difficult to treat.7,46 With CHF predominantly affecting the elderly, fatigue is often dismissed as a consequence of ageing and deconditioning and is therefore poorly recognized or explored.14 Education of patients and carers on how to assess and manage fatigue could therefore improve

| Symptom | Name of assessment tool with validation reference | Description | Structure | Strengths | Limitations |
|---------|--------------------------------------------------|-------------|----------|----------|-------------|
| Fatigue | Hospital Anxiety and Depression Scale | Assesses patient depressive and anxiety symptoms | Overall maximum score of 15, with 5 and above indicating a diagnosis of depressive disorder | Concise and self-administered, therefore practical for clinical use | Limited validation in large Danish cohort, limited validation in large Danish cohort |
|         | Patient Health Questionnaire | Assesses patient for depressive symptoms | 14-item self-assessment scale | Well validated, repeatable, and responsive | Unclear cut-off rate for screening and accuracy |
|         | ADL, activities of daily living | Quality of life | 10-item self-reporting questionnaire | Concise and self-administered | Limited validation in large Danish cohort |
|         | BDI, Baseline Dyspnoea Index | QoL | Patients answer questions using a score from 0 (not at all) to 3 (nearly every day) | Correlates with readmission and QoL | Validation limited by small sample size |
|         | ID, Index of Dyspnoea – Fatigue Index | QoL | Structured interview of seven questions | Correlates with readmission and QoL | Validation limited by small sample size |

ADL, activities of daily living; BDI, Baseline Dyspnoea Index; CHF, chronic heart failure; QoL, quality of life; TDI, Transition Dyspnoea Index.
patient-oriented outcomes. Despite not being validated in CHF, the 20-item Multidimensional Fatigue Inventory has been frequently utilized in CHF studies.\textsuperscript{14,47} The tool is comprehensive and assesses general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity.\textsuperscript{48} However, a number of tools validated for CHF include fatigue as one of their domains (Table 1). Fatigue has significant overlap with other symptoms found in CHF. As well as affecting functional status, fatigue is closely associated with depression; Falk et al.\textsuperscript{14} found that reduced activity was associated with low motivation in CHF patients. Significant dyspnoea also appears to worsen physical fatigue suggesting better symptom management could improve exercise intolerance and consequently mood.\textsuperscript{14} There is limited guidance on how to effectively treat fatigue because emotional and psychological factors play a major role in the experience of physiological fatigue.\textsuperscript{46,49} A multidisciplinary approach involving cardiologists, psychological support, physiotherapists, sleep specialists, and dieticians has been proposed.\textsuperscript{10}

### Dyspnoea

Breathlessness is a key symptom of CHF. Goebel et al.\textsuperscript{50} found that 61.7% of 96 CHF patients reported shortness of breath with breathlessness being the most common complaint prompting a hospital consultation.\textsuperscript{1,10,51} Dyspnoea is thought to be due to a combination of factors including diaphragmatic or skeletal muscle weakness, deconditioning, obesity, anaemia, pulmonary oedema, or lung stiffness due to elevated left ventricular pressure.\textsuperscript{10,45,50} Similar to fatigue, dyspnoea is often underappreciated and seen as a by-product of ageing and reduced fitness.\textsuperscript{45} The patient experience of dyspnoea is highly variable and can significantly reduce morale.\textsuperscript{10} Breathlessness can be episodic or continuous, ranging from an uncomfortable awareness of breathing to a feeling of suffocation or breathlessness.\textsuperscript{1,10,51} It is often frightening and has a psychological impact.\textsuperscript{10,45,52,53} A multivariable analysis of the COMET study found breathlessness to be the only symptom that was a significant predictor of mortality.\textsuperscript{52} Thus, the accurate assessment of dyspnoea is especially important due to its long-term implications to hospitalization and prognosis.

Dyspnoea is often ranked numerically or with ‘Likert’ scales based on how it impacts activities of daily living and thereby QoL.\textsuperscript{10,51} The commonly utilized NYHA class has variable sensitivity in gauging dyspnoea and classifying patients.\textsuperscript{51} Assessment of dyspnoea is challenging because patient activity level affects their sense and the impact of dyspnoea on QoL. There is no agreed questionnaire for dyspnoea in CHF,\textsuperscript{51} so we have summarized the available tools for the assessment of dyspnoea (Tables 1 and 2). While many of these questionnaires have been validated for reproducibility with some correlating to prognosis, in general, they lack sensitivity to acute changes in dyspnoea or specificity to CHF with some too long or under copyright to be practical for routine clinical use.\textsuperscript{51} Treating dyspnoea requires assessment of the cause, which in people without pulmonary oedema remains controversial. If due to pulmonary or peripheral congestion, loop diuretics are highly effective with renin–angiotensin system antagonists useful in preventing reaccumulation. Device therapies such as cardiac resynchronization therapy and left ventricular assist devices are also associated with reduced dyspnoea.\textsuperscript{58,59} A greater focus on symptoms could enable promising alternative therapies such as relaxin and sildenafil to explore further which have been yet to be formally approved due to unimproved mortality and hospitalization.\textsuperscript{60}

### Cough

Cough is a protective reflex that encourages the clearing of secretions or foreign particles from the larynx, trachea, and large bronchi. The mechanism is triggered by irritation of mechanical and chemical receptors located in trachea, bronchi, and smaller airways.\textsuperscript{61} Despite over 40% of CHF patients complaining of cough, it remains a symptom that is missed from commonly used tools such as the NYHA scale.\textsuperscript{3,11} In CHF, cough is commonly either due to pulmonary congestion or secondary to angiotensin-converting enzyme inhibitors through an accumulation of bradykinin and prostaglandins.\textsuperscript{52} Persistent cough causes breathlessness, fatigue, and chest pain, disrupting activity and sleep.\textsuperscript{1,18,63} Chronic cough can also have a considerable psychological impact on CHF patients through inconvenience, embarrassment, frustration, and incontinence, thereby contributing to depression.\textsuperscript{64,65} On the other hand, an inability to efficiently cough, for instance, due to fatigue or breathlessness, can cause increased susceptibility to infection due to secretion retention.\textsuperscript{66} Cough
| Name of assessment tool | Description | Structure | Strengths | Limitations |
|-------------------------|-------------|-----------|-----------|-------------|
| Borg Scale | Assesses dyspnoea during cardiopulmonary exercise testing | Dyspnoea during exercise is ranked 0–10 (0 = no perceived dyspnoea and 10 = maximal dyspnoea) | Simple to use and commonly utilized in the research setting | It is estimated one in every two to three CHF patients are unable to conduct CPET appropriately.55,56 |
| Chronic Respiratory Disease Questionnaire | Assesses impact of dyspnoea on overall well-being: similar to the Chronic Heart Failure Questionnaire | Dyspnoea is rated using 1–7 scale, where 1 = extremely breathless and 7 = not breathless at all, in relation to five activities of daily living (ADLs) selected by patient. Includes standardized questions regarding emotional function and fatigue | Patient-specific survey | Patient specificity makes this tool less useful for inter-patient comparisons. |
| Medical Research Council Dyspnoea Scale | Assesses dyspnoea in relation to ADL | Patients give a 1–5 score, ranging from 1 being ‘not troubled by breathlessness except on strenuous exercise’ to 5 being ‘too breathless to leave the house, or breathless when undressing’ | Can be used in follow-up visits to track change in dyspnoea | Lacks sensitivity to track responses to therapy in a single hospital stay, therefore inappropriate for hospitalized patients. This method has not been validated specifically in relation to CHF. |
| Oxygen cost diagram | Assesses dyspnoea in relation to ADLs | Rating corresponding to the oxygen requirements of 13 different activities ranked from 0 to 100. Sitting, sleeping, or standing are ranked close to 0 as they are low oxygen demand. Walking briskly/ Uphill would be closer to 100. A score of 100 indicates no impairment | Indicates patient’s perception of their exercise tolerance | Subjective—does not correlate well with objective changes to exercise capacity. CHF patients may be incapable of completing all 13 ADLs, due to co-morbidities or other symptoms, thus reducing value of this approach. |
| St. Georges Respiratory Questionnaire | Assesses impact of dyspnoea on overall well-being | Self-completed form of 76 questions measuring symptom frequency and severity (rated with a 0–5 Likert scale) and their relation to ADLs (yes/no questions) | Comprehensive | Lengthy |
| University of California San Diego Shortness of Breath Questionnaire | Assesses dyspnoea in relation to ADL | Patients answer questions on a scale of 0 (no breathlessness) to 5 (unable to complete due to breathlessness). Consists of 21 questions about the severity of dyspnoea associated with various ADLs | Comprehensive | Lacks sensitivity to track changes across a day or week. CHF patients may be incapable of completing some ADLs in questionnaire due to co-morbidities or other. |

(Continues)
is often overlooked in clinic, even by the patients and carers themselves in favour of issues such as dyspnoea and fatigue. Hence, although cough is highly prevalent in CHF, there is little literature addressing its impact and formal assessment. Assessment of cough involves exploring several components including intensity, frequency, and disruptiveness. Table 3 provides a summary of three cough assessment tools, although none is especially frequently used. These symptom surveys could be used in conjunction with ambulatory cough monitors to assess cough frequency, severity, and impact on QoL. While these surveys have been shown to be well validated and responsive, none have been designed or validated for CHF specifically. Cough is also included in some wider symptom surveys, such as the Memorial Symptom Assessment Scale and the Symptom Distress Scale (Table 4). The treatment of cough in CHF is incomplete and focuses around reducing pulmonary oedema with the use of diuretics and removing possible contributors such as angiotensin-converting enzyme inhibitors. There is a need to develop further management options.

Peripheral oedema

Peripheral oedema, found in over 50% of CHF patients, is a well-known sign of the condition but also features as a symptom. It is normally a result of right-sided heart congestion and can range from mild episodic ankle swelling to severe generalized fluid retention. While oedema commonly manifests in the distal limbs, severe peripheral oedema can present alongside ascites, scrotal congestion, and even subconjunctival oedema. Oedema is uncomfortable at best and can limit exercise capacity, resulting in disturbed sleep, pain, and increased risk of infection. Early detection of oedema may avoid complications such as ulcers, bed sores, stasis eczema, and cellulitis. Unfortunately, patients often fail to appreciate mild peripheral oedema due to its insidious development and mistake it for normal weight gain such that oedema may not be reported until 20 L of fluid has accumulated. Many patients have little appreciation of the significance or the knowledge of how to adjust their diuretic dose. Education to facilitate self-care is required to tackle this issue. Peripheral swelling is included in most symptom questionnaires because weight gain can be masked by cachexia. Newer optical scanners utilize non-contact depth sensing methods to create advanced 3D images for determining changes in leg shape, size, and consistency. Hence, novel approaches to oedema monitoring are needed to build a model of disease progression and facilitate patient-directed diuretic dose adjustment, balancing the risk of renal impairment.
Pain

Pain is an under-recognized yet debilitating symptom of CHF, which can range in characteristic from musculoskeletal ache, deep visceral pain, and neuropathic pain, all of which are reported at a similar prevalence to dyspnoea in end-stage CHF.66,68 For example, the PAIN-HF study reported that 84% of 347 patients with advanced CHF complained of pain, and 70% believe it interfered with activities of daily living. While pain was most commonly cited in the legs and back, more than a third experience pain in multiple sites.65 Pain can be challenging to classify and find the source,66 particularly in CHF where ageing, co-morbidities, and general deconditioning commonly coexist.65 Pain also has significant overlap with other CHF symptoms such as breathlessness, low mood, and poor sleep. One overlooked adverse effect of pain is its autonomic response, which can further activate the renin–angiotensin–aldosterone cascade.67 Pain severity is usually rated on a scale of 1–10. Its subjective nature is problematic, particularly for inter-patient comparisons. A carefully taken history coupled with standardized and repeated assessment has a key role. Lower levels of pain or good pain control are associated with better medication adherence, improved ability to self-report symptoms and self-care implying benefits beyond simply improved QoL.67,88 For example, the diagnosis of chronic pain makes patients four times more likely to be diagnosed with depression.89 The most common treatments for pain include paracetamol, non-steroidal anti-inflammatory drugs, and opiates. Opiates have an important role in CHF both in the early and later palliative stages of the disease and are safe, well tolerated, and effective.85 Conversely, non-steroidal anti-inflammatory drugs can increase the risk of progression of CHF as well as the frequency of adverse events, making its use controversial.90 A number of non-medical alternatives have been suggested, such as the use of hot or cold patches and stretching exercises.91 As with the other less frequently discussed symptoms, there are limited data available on appropriate analgesia or non-medical intervention for pain relief in CHF. Moving to symptom-focused pathways of care with repeated testing will help identify prevalence and course of symptoms and develop standardized approaches to the treatment of this distressing symptom.
| Name of assessment tool with validation reference | Structure | Strengths | Limitations | Validated in CHF |
|------------------------------------------------|-----------|-----------|-------------|----------------|
| Cardiac Health Profile of Congestive Heart Failure | ● 10-item self-assessment tool <br>● Covers both disease-specific and general areas of heart failure issues | ● Correlates well with the MLHFQ, maximal workload during exercise and NYHA | ● Women were poorly represented in the validation study. | Yes<sup>59,121</sup> |
| Care-Related Quality of Life survey for Chronic Heart Failure | ● 20-item self-assessment tool covering a range of concerns from physical, emotional, and social | ● Adds new concepts to CHF assessment primarily around patient anxiety | ● Requires further validation work into the discriminatory properties of the tool | No |
| Chronic Heart Failure Questionnaire | ● 16-item interview-administered assessment tool | ● Able to detect changes over time | ● Interviewer required <br>● Can be difficult to conduct inter-patient analysis <br>● Requires licensing for use | No |
| Edmonton Symptom Assessment Scale | ● 10-item self-assessment tool <br>● Uses 0–10 to rate their level of distress from pain, fatigue, nausea, depression, anxiety, sleepiness, appetite, dyspnoea, and ‘other’ symptoms | ● Can be self-administered <br>● Widely used | ● Not heart failure specific | Yes (including revised version)<sup>70</sup> |
| Heart Failure Somatic Awareness Scale | ● 12-item self-assessment tool to measure awareness of and distress secondary symptoms | ● Actively developed for further utilization <br>● Simple to use and relatively quick to use | ● Small population for validation study | Yes<sup>71</sup> |
| Kansas City Cardiomyopathy Questionnaire | ● 23-item self-assessment tool covering six domains: physical limitation, symptom, symptom stability, self-efficacy, QoL, and social limitation | ● Can be self-administered <br>● Can be completed within 10 min | ● Lengthy | Yes (including short version)<sup>72</sup> |
| The Left Ventricular Dysfunction Questionnaire | ● 36-item self-assessment tool, which are answered true or false | ● Useful for monitoring change in symptoms and scores correlated well to the patient’s perception of change | | |
| Multidimensional Index of Life Quality | ● 35-item self-assessment tool covering nine domains ranging from physical health and function to financial status and social circumstances | ● Depicts global QoL | ● Not heart failure specific <br>● Some domains score poorly on retest reliability. | No |

(Continues)
| Name of assessment tool with validation reference | Structure | Strengths | Limitations | Validated in CHF |
|-------------------------------------------------|-----------|-----------|-------------|-----------------|
| MLHFQ                                           | ● 21-item self-assessment tool covering three domains: physical, socioeconomic, and psychological<br> ● Mainly focuses on dyspnoea, fatigue, and emotional aspects | ● Can be self-administered<br> ● Can be completed within 10 min | ● Lengthy | Yes$^{74}$ |
| Memorial Symptom Assessment Scale-Heart Failure  | ● 32-item symptom assessment scale<br> ● Three symptom subscales: physical, emotional, and heart failure-specific symptoms<br> ● Uses Likert scales to rate overall frequency, intensity, and distress associated with 35 common symptoms | ● Comprehensive and well validated | ● Requires licensing for use | Yes$^{11}$ |
| Symptom distress scale                          | ● 15-item assessment tool<br> ● Uses Likert scales to assess impact of symptoms<br> ● Mainly focuses on fatigue, insomnia, mood, mobility, concentration, breathing, pain, nausea, and appearance | ● Personalized to the patient | ● Not heart failure specific<br> ● Ambiguity in interpretation of questions | No |
| Short Form Health Survey                        | ● 36-item self-assessment tool covering two domains: physical health and mental health<br> ● Uses Likert scales to assess pain, general health, vitality, social functioning, emotional, and mental health | ● Can be self-administered<br> ● Depicts global QoL | ● Not heart failure specific | Yes$^{75}$ |
| Sickness impact profile                         | ● 68-item generic health measure<br> ● Assesses autonomy, mobility, behaviour, feelings, and communication | ● Depicts global QoL | ● Not heart failure specific<br> ● Lengthy | No |
| Symptom Status Questionnaire–Heart Failure      | ● 7-item self-assessment tool for measuring the patient’s perception to physical CHF symptoms with five response options ranging from 0 (none) to 4 (experienced nearly daily) | ● Short and easy to complete | ● Narrow focus of CHF symptoms experienced | Yes$^{76}$ |
| Quality of Life Questionnaire in Severe Heart Failure | ● 26-item self-assessment tool with a combination of visual analogue and Likert scales | ● Includes emotional and cognitive aspects of QoL in addition to general satisfaction | ● Small population for validation study<br> ● Limited utilization in modern CHF research | Yes$^{77}$ |

CHF, chronic heart failure; MHLQ, Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association; QoL, quality of life.
Low mood

A 2006 meta-analysis of 36 studies determined that ~22% of CHF patients are diagnosed with ‘clinically significant’ depression.\(^9\) CHF-associated depression is more common in patients with co-morbidities, rapid disease progression, or younger age at presentation.\(^9\) Depression is also commonly overlooked due to overlapping signs and symptoms such as fatigue.\(^10\) Furthermore, the wide array of possible tools and thresholds of depressive symptoms often without standardization makes low mood difficult to assess confidently. The exact aetiology of low mood is often unclear in individual patients. CHF patients are at risk of feelings of worthlessness and guilt as they become increasingly dependent on carers.\(^9,95\) This is often preceded by or can lead to a vicious cycle of reduced activity and motivation, worsening health status, and increasing dependence.\(^14\) Faris et al.\(^96\) studied 396 patients with CHF and found that in comparison with those without depression, depression was associated with worse symptoms of longer duration, higher risk of hospital admission, and a doubling of mortality rate. Once it is recognized, treatment of depression is associated with improved QoL and medical adherence.\(^97\) Moreover, because depression has an adverse effect on the autonomic nervous system, it could worsen the pathophysiological drivers of the syndrome,\(^96\) thereby explaining the heightened risk of disease progression and poorer overall outcomes including hospitalization rates and sudden cardiac death.\(^97–102\) Worsening depression over a year is also a bad omen, hinting that regular monitoring could allow early intervention with the aim of improving outcomes.\(^100\) A number of mood assessment tools are available including the Hospital Anxiety and Depression Scale, Geriatric Depression Scale–Short Form, and the Patient Health Questionnaire-9 (Table 4). These questionnaires are used variably across clinical environments and have a number of advantages and shortcomings (Table 3).\(^99\) Only the Patient Health Questionnaire-9 has been shown to correlate with QoL and readmission in CHF.\(^103,104\) Treating low mood can be done safely with pharmacological treatments such as selective serotonin reuptake inhibitors,\(^105\) whereas tricyclic antidepressants and monoamine oxidase inhibitors should be avoided because of the increased risk of arrhythmias or hypotension.\(^106\) Non-pharmacological interventions such as psychotherapy, such as cognitive behaviour therapy and exercise, have also shown to be successful methods of managing depression in CHF but have limited availability.\(^107,108\) Early identification and management of low mood may slow deterioration and may therefore improve CHF-specific outcomes.

Existing strategies for symptom assessment in chronic heart failure

Patient-reported outcomes (PROs) are question-based tools that quantify QoL by assessing symptom frequency and severity according to the patient’s perspective that can be applied systematically at each encounter.\(^109\) Disease-specific PROs can be used to form a picture of the patient’s current disease status and overall well-being both at baseline and compared with previous assessments. This enables a systematic approach for obtaining QoL data that are inexpensive and effective.\(^52\) PROs have been shown to provide a more accurate overall picture of disease status than physiological assessments such as left ventricular ejection fraction.\(^95\) Furthermore, a general clinical assessment of symptoms often varies by healthcare professionals such that structured questionnaires could improve consistency in clinical care.\(^110\) Despite a plethora of available tools (31 that we could find) with some use in clinical research, they are infrequently used to guide clinical practice.\(^95\) We have reviewed a number of PROs available (Table 4) including the three most commonly cited questionnaires: the MLHFQ, the Kansas City Cardiomyopathy Questionnaire (KCCQ), and the Edmonton Symptom Assessment System—Revised. Developed in 1987, the MLHFQ provides scores based on physical and emotional symptoms. It is frequently used in CHF due to its ease and familiarity,\(^111\) and it predicts event-free survival following CHF decompensation with utility in identifying changes in the patient’s QoL and outcomes.\(^112\) The KCCQ quantifies health status with a higher score indicating better health predictive of hospitalization and cardiovascular risk.\(^111\) The KCCQ has since been shortened to consist of 12 questions, to improve accessibility.\(^113,114\) This shorter questionnaire has positive correlations with the original, high test–retest reliability and responsiveness.\(^113\) Bekelman et al.\(^6\) concluded that KCCQ should be used as a clinical indicator for palliative needs; however, neither the KCCQ nor the MLHFQ comprehensively assesses physical, psychological, and social health contributors to QoL.\(^95\) The Edmonton Symptom Assessment System has been validated and translated in over 20 different languages.\(^115\) It was originally created to document symptoms in end-stage cancer patients requiring palliative care and has since been revised into a simpler and more patient-friendly tool known as the Edmonton Symptom Assessment System—Revised. It is quick to complete and in contrast to other tools is highly accessible through generous licensing agreements.\(^84\) Patient-reported outcomes in CHF are validated and reproducible and are increasingly utilized as secondary outcomes in clinical trials such as the Angiotensin–Nepriysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) study\(^116\) and the upcoming Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction (Empire HF) trial.\(^117\) In due course, given that death and hospitalization have a significant impact on patient QoL, it is feasible that PROs could move towards becoming primary outcome measures. Moreover, in patients reaching end of life, PROs could direct medical care away from measures to enhance survival and towards those that enhance remaining life.\(^118\) The utility of
these tools may be enhanced further by being accessible for patients to help them assess their own health status. Outstanding issues around existing PROs that may explain the relative lack of uptake include cost, copyright, practical implementation, lack of breadth of symptoms, challenges around presentation, issues around credibility of results, and the focus on survival for approval of new interventions. Many of these issues would be solved with familiarity and validated modification for local needs. It is already the case that over 70% of healthcare professionals questioned by Wohlfahrt et al. believed that PRO assessment should become routine in clinical care, and emerging data confirm that integration into a standard CHF clinic is feasible and acceptable to patients. The restructuring of clinical services away from face-to-face reviews with a greater emphasis on digital technologies presents a challenge but one in which PROs could take a leading role for routine care and research activity. Indeed, this approach has been shown to be both feasible and valuable by Stehlik et al. in the clinic setting, finding the average time of completion to be 6.7 min with 91% of started assessments completed fully. We believe this approach will not only improve recognition of the plethora of manageable symptoms associated with CHF but also aid standardization, initiation of required therapy, assessment of intervention response, and the clinical consultation itself.

Summary

Chronic heart failure leads to symptoms in patients across a range of domains that are frequently poorly assessed. We believe there are opportunities to improve patient contact episodes to identify underlying problems and improve clinical management in a holistic fashion. It seems both feasible and essential for a PRO to be implemented in a clinical environment such as outpatient clinics, thus adding value to the consultation and monitoring improvements in patients and the CHF population.

Conflict of interest

A.K. is enrolled on a PhD fellowship programme partly funded through a collaborative unconditional research grant to the University of Leeds from Medtronic UK. K.K.W., M.T.K., and R.M.C. have received unconditional research support from Medtronic; K.K.W. has served as an advisor for Medtronic, an advisor, speaker, and proctor for Cardiac Dimensions, and a speaker and advisor for Novartis, Bayer, Napp, Pfizer, and Daiichi Sankyo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

1. Patel H, Shafazand M, Schaufelberger M, Ekman I. Reasons for seeking acute care in chronic heart failure. Eur J Heart Fail 2007; 9: 702–708.
2. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC. Heart failure: preventing disease and death worldwide. Esc Heart Fail 2014; 1: 4–25.
3. Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manage 2008; 35: 594–603.
4. Buckberg GD. Congestive heart failure: treat the disease, not the symptom—return to normalcy. J Thorac Cardiovasc Surg 2001; 121: 628–637.
5. Jaarsma T, Leventhal M. End-of-life issues in cardiac patients and their families. Eur J Cardiovasc Nurs 2002; 1: 223–225.
6. Bekelman DB, Rumsfeld JS, Havranek EP, Yamashita TE, Hurr E, Gottlieb SH, Dy SM, Kuttner JS. Symptom burden, depression, and spiritual well-being: a comparison of heart failure and advanced cancer patients. J Gen Intern Med 2009; 24: 592–598.
7. Witte KK, Clark AL. Why does chronic heart failure cause breathlessness and fatigue? Prog Cardiovasc Dis 2007; 49: 366–384.
8. Witte KK, Drozd M, Walker AMN, Patel PA, Kearney JC, Chapman S, Sapsford RJ, Gierula J, Paton MF, Lowry J, Kearney MT, Cubbon RM. Mortality reduction associated with beta-adrenoceptor inhibition in chronic heart failure is greater in patients with diabetes. Diabetes Care 2018; 41: 136–142.
9. Allen LA, Tang F, Jones P, Breeding T, Ponirakis A, Turner SJ. Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: insights from the NCDR PINNACLE® registry. BMC Cardiovasc Disord 2018; 18: 80.
10. Alpert CM, Smith MA, Hummel SL, Hummel EK. Symptom burden in heart failure: assessment, impact on outcomes, and management. Heart Fail Rev 2017; 22: 25–39.
11. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs 2005; 4: 198–206.
12. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, aids, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31: 58–69.
13. Brannstrom M, Roman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail 2014; 16: 1142–1151.
14. Falk K, Patel H, Svedberg K, Ekman I. Fatigue in patients with chronic heart failure—a burden associated with emotional and symptom distress. Eur J Cardiovasc Nurs 2009; 8: 91–96.
15. McClain CS, Rosenfeld B, Breitbart W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet 2003; 361: 1603–1607.
16. Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnaic JW, Abrahman WT, Kasper EK, Rogers JG, Califf RM, Schramm EE, O’Connor CM. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardio 2008; 52: 1702–1708.
17. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW.
Prioritizing symptom management in the treatment of chronic heart failure

Preferences for quality of life or survival expressed by patients with heart failure. *J Heart Lung Transplant* 2001; 20: 1016–1024.

18. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. *Heart Fail Rev* 2002; 7: 9–16.

19. National Institute for Cardiovascular Outcomes Research (NICOR). National heart failure audit: 2016/17 summary report. 2018.

20. Moser DK, Frazier SK, Worrall-Carter L, Biddle MJ, Chung ML, Lee KS, Lennie TA. Symptom variability, not severity, predicts rehospitalization and mortality in patients with heart failure. *J Cardiaco Nurs* 2011; 20: 124–129.

21. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Jankowska EA, Jessup M, Linde C, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, González-Juanatey JR, Harjola VP, Gerberuzzi MI, Coats AJ, Belenkov YN. Cardiac Depression Scale in patients with cardiac disease: results from the DenHeart survey. *Health Qual Life Outcomes* 2020; 18: 9.

22. Tiesinga LJ, Dassen TW, Halfens RJ. Fatigue Scale. *Int J Nurs Stud* 2005; 42: 509–515.

23. Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea–fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. *Am J Cardiaco* 2003; 94: 65–69.

24. Lee EJ, Hall LA, Moser DK. Psychometric properties of the Patient Health Questionnaire (PHQ)-9 in patients with heart failure and gastrointestinal symptoms. *J Nurs Meus* 2014; 22: E29–E40.

25. Yorke J, Moosavi SH, Shulham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. *Thorax* 2010; 65: 21–26.

26. Kuo SH, Schulman S, Starling RC, Jessup M, Wentworth D, Burkhoff D. Development and validation of a patient questionnaire to determine New York Heart Association classification. *J Cardiac Fail* 2004; 10: 228–235.

27. Lalhou-Laforêt K, Ledru F, Niara R, Consoli SM. Validity of Beck Depression Inventory for the assessment of depressive mood in chronic heart failure patients. *J Affect Disord* 2015; 184: 256–260.

28. Wise FM, Harris DW, Carter LM. Validation of the Cardiac Depression Scale in a cardiac rehabilitation population. *J Psychosom Res* 2006; 60: 177–183.

29. Christensen Ov, Dixon JK, Juel K, Ekholm Ov, Rasmussen TB, Borregaard B, Mols RE, Thrysoe L, Thorup CB, Berg SK. Psychometric properties of the Danish Hospital Anxiety and Depression Scale in patients with cardiac disease: results from the DenHeart survey. *Health Qual Life Outcomes* 2020; 18: 9.

30. Hammash MH, Hall LA, Lennie TA, Heo S, Chung ML, Lee KS, Moser DK. Psychometrics of the PHQ-9 as a measure of depressive symptoms in patients with heart failure. *Eur J Cardiovasc Nurs* 2013; 12: 446–453.

31. Arena R, Myers J, Guazzi M. The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review. *Heart Fail Rev* 2008; 13: 245–269.

32. Florea VY, Mareyev VY, Achilov AA, Popovic MI, Coats AJ, Belenkov YN. Central and peripheral components of chronic heart failure: determinants of exercise tolerance. *Int J Cardiac* 1999; 70: 51–56.

33. Wolsk E, Kaye D, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D, Kitzman DW, Lam CSP, van Veldhuisen DJ, Ponikowski P, Petrie MC, Hassager C, Møller J, Gustafsson F. Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction. *Jacc Heart Fail* 2019; 7: 321–332.

34. Garnham JO, Roberts LD, Espino-Gonzalez E, Whitehead A, Swoboda PP, Koshy A, Gierula J, Paton MF, Cubbon RM, Kearney MT, Egginton S. Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology. *J Cachexia Sarcomopenia Muscle* 2019; 11: 394–404.

35. Del Buono MG, Arena R, Borlaug BA, Carboni G, Guazzi M, Kirkman DL, Garten R, Rodriguez-Miguélez P, Guazzi M, Lavie CJ, Abbate A. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. *J Am Coll Cardiol* 2019; 73: 2209–2225.

36. Kokkinos P, Myers J, Kokkinos JP, Pittaras A, Narayan P, Manolis A, Karasik P, Greenberg M, Papademetriou V, Singh S. Exercise capacity and mortality in Black and White men. *Circulation* 2008; 117: 614–622.

37. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough F, Rees K, Singh S. Exercise-based rehabilitation for heart failure. *Cochrane Database Syst Rev* 2014; 4: CD003331.

38. Witte KK, Byrom R, Gierula J, Paton MF, Jami AL, Lowry JE, Gilroy RG, Barnby SA, Chemun H, Kearney LC, Greenwood JP, Plein S, Law GR, Pavitt S, Barth JH, Cubbon RM, Kearney MT. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. *J Am Coll Cardiol* 2016; 67: 2593–2603.

39. Ingle L, Shelton RJ, Rigby AS, Nabb S, Clark AL, Cleland JG. The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. *Heart* 2005; 89: 1742–1751.

40. Bensimhon DR, Leifer ES, Ellis SJ, Fleg JI, Keteyian SJ, Piai IL, Kitzman DW, McKelvie RS, Kraus WE, Forman DE, Kao AJ. Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training). *Am J Cardiol* 2008; 102: 712–717.

41. Vitale C, Ilaria S, Rosano GM. Pharmacological interventions effective in improving exercise capacity in heart failure. *Card Fail Rev* 2018; 4: 25–27.

42. Piia IL, Apstein CS, Balady GJ, Belardinnelli R, Chaitman BR, Duscha BD, Fletcher BJ, Fleg JI, Myers JN, Sulivan MJ. Exercise and heart failure. *Circulation* 2000; 102: 316–40.

43. Auricchio A, Kloss M, Trauttel SI, Rodner S, Klein H. Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. *Am J Cardiol* 2002; 89: 198–203.

44. Ekmann I, Cleland JGF, Andersson B, Swedberg K. Exploring symptoms in chronic heart failure. *Eur J Cardiovasc Nurs* 2005; 91: 225–226.

45. Jones J, McDermott CM, Novels CT, Matlock DD, Beldeman DB. The experience of fatigue as a distressing symptom of heart failure. *Heart Lung* 2012; 41: 484–491.

46. Falk K, Swedberg K, Gaston-Johansson F, Ekmann I. Fatigue and anaemia in patients with chronic heart failure. *Eur J Heart Fail* 2005; 7: 699–703.

47. Jones J, McDermott CM, Novels CT, Matlock DD, Beldeman DB. The experience of fatigue as a distressing symptom of heart failure. *Heart Lung* 2012; 41: 484–491.

48. Falk K, Swedberg K, Gaston-Johansson F, Ekmann I. Fatigue and anaemia in patients with chronic heart failure. *Eur J Heart Fail* 2005; 7: 699–703.

49. Hagglund L, Boman K, Olofsson M, Brulin C, Fatigue and health-related quality of life in elderly patients with and without heart failure in primary healthcare. *Eur J Cardiovasc Nurs* 2007; 6: 208–215.

50. Falk K, Granger B, Swedberg F, Ekmann I. Breaking the vicious circle of fatigue in patients with chronic heart failure. *Qual Health Res* 2007; 17: 1020–1027.

51. Goebel JR, Doering IV, Shugarnar LM, Asch SM, Sherbourne CD, Lanto AB, Evangelista LS, Nyamathai AM, Malisi SL, Lorenz KA. Heart failure: the hidden problem of pain. *Patient Symptom Manage* 2009; 38: 697–707.

52. West RL, Hernandez AF, O’Connor CM, Starling RC, Calififf RM. A review of dyspnea in acute heart failure syndromes. *Am Heart J* 2010; 160: 209–214.
review and position paper by the Working Group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. *Eur Heart J* 2016; 37: 1015–1023.

91. McDonald DD, Sourat C, Chan MA, Afriyie A. A closer look: alternative pain management practices by heart failure patients with chronic pain. *Heart Lung* 2015; 44: 395–399.

92. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure. *J Am Coll Cardiol* 2006; 48: 1527–1537.

93. Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, Murray SA, Grodzicki T, Bergh I, Metra M, Ekmann, Angermann C, Leventhal M, Pitsis A, Anker SD, Gavazzi A, Ponikowski P, Dickstein K, Delacretaz E, Blue I, Strasser F, McMurray J, on behalf of the Advanced Heart Failure Study Group of the HFA of the ESC. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2009; 11: 433–443.

94. Holzapfel N, Muller-Tasch T, Wild B, Jungre J, Zugck C, Remppis A, Herzog W, L"owe B. Depression profile in patients with and without chronic heart failure. *J Affect Disord* 2008; 105: 53–62.

95. Kelkar AA, Sperutz J, Pang P, Pierson RF, Cody RJ, Pina II, Hernandez A, Butler J. Utility of patient-reported outcome instruments in heart failure. *JACC Heart Fail* 2016; 4: 165–175.

96. Faris R, Purcell H, Henein MY, Coats AJ. Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure. *Eur J Heart Fail* 2002; 4: 541–551.

97. Connorsney I, Shapiro PA. Assessment of depression in heart failure patients: what is the role for cardiology? *J Am Coll Cardiol* 2011; 57: 424–426.

98. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O’Connor CM, Adams KF Jr, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH. Relationship of depression to death or hospitalization in patients with heart failure. *Arch Intern Med* 2007; 167: 367–373.

99. O’Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Callif RM, Krishnan RR. Antidepressant use, depression, and survival in patients with heart failure. *JAMA Intern Med* 2008; 168: 2232–2237.

100. Sherwood A, Blumenthal JA, Hinderliter AL, Koch GG, Adams KF Jr, Dupree CS, Bensimhon DR, Johnson KS, Trivedi R, Bowers M, Christenson RH, O’Connor CM. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. *J Am Coll Cardiol* 2011; 57: 418–423.

101. Son YJ, Seo EJ. Depressive symptoms and physical frailty in older adults with chronic heart failure: a cross-sectional study. *Res Gerontol Nurs* 2018; 11: 160–168.

102. Mbakwem A, Aina F, Amadi C. Expert opinion-depression in patients with heart failure: is enough being done? *Card Fail Rev* 2016; 2: 110–112.

103. Bhatt KN, Kalogeropoulos AP, Dunbar SB, Butler J, Georgioupolous VV. Depression in heart failure: can PHQ-9 help? *Int J Cardiol* 2016; 221: 246–250.

104. Beach SR, Januzzi JL, Mastromarco CA, Healy BC, Beale EE, Celano CM, Huffman JC. Patient Health Questionnaire-9 score and adverse cardiac outcomes in patients hospitalized for acute cardiac disease. *J Psychosom Res* 2013; 75: 409–413.

105. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakkary B, Stough WG, Arias RM, Rivelli SK, Krishnan R. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. *J Am Coll Cardiol* 2010; 56: 692–699.

106. Shapiro PA. Treatment of depression in patients with congestive heart failure. *Heart Fail Rev* 2009; 14: 7–12.

107. Gary RA, Dunbar SB, Higgins MK, Musselman DL, Smith AL. Combined exercise and cognitive behavioral therapy improves outcomes in patients with chronic heart failure. *J Psychosom Res* 2010; 69: 119–131.

108. Blumenthal JA, Babyak MA, O’Connor C, Ketyeay S, Landzberg J, Howlett J, Kraus W, Gottlieb S, Blackburn G, Swank A, Beltran DJ. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. *JAMA* 2012; 308: 465–474.

109. Sperutz J. Barriers to the use of patient-reported outcomes in clinical care. *Circ Cardiovasc Qual Outcomes* 2014; 7: 2–4.

110. Ehrenberg A, Ehnfors M, Ekmann I. Older patients with chronic heart failure within Swedish community health care: a record review of nursing assessments and interventions. *J Clin Nurs* 2004; 13: 90–96.

111. Garin O, Herdman M, Vilagut G, Ferrer M, Ribera A, Rajmil L, Valderas JM, Guillemin F, Revicki D, Alonso J. Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. *Heart Fail Rev* 2014; 19: 359–367.

112. Moser DK, Yamokakis L, Sun J, Conway GA, Hartman KA, Graziano JA, Binanay C, Stevenson LW, Escape Investigators. Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. *J Card Fail* 2009; 15: 763–769.

113. Sperutz J, A, Jones PG. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. *Circ Cardiovasc Qual Outcomes* 2015; 8: 469–476.

114. Sepehrvand N, Ezekowitz JA. How to do more with less. *Circ Cardiovasc Qual Outcomes* 2015; 8: 460–462.

115. Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years later: past, present, and future developments. *J Pain Symptom Manage* 2017; 53: 630–643.

116. McMurray JIV, Packer M, Desai AS, Gorg J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014; 371: 993–1004.

117. Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, Keber L, Gustafsson F, Fosbol E, Bruun NE, Videbeek L, Frederiksen PH, Möller JE, Schou M. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). *Trials* 2019; 20: 374.

118. Kraai IH, Vermeulen KM, Luttik ML, Hoekstra T, Jaarsma T, Hillege HL, Bech P. Preferences of heart failure patients in daily clinical practice: Quality of life or longevity? *Eur J Heart Fail* 2013; 15: 1113–1121.

119. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekmann I, Filippatos GS. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail* 2013; 15: 1082–1094.

120. Wohlfahrt P, Zickmund SL, Slager S, Allen LA, Nicolau J, Konty AG, Felker GM, Conte J, Flint K, DeVore AD, Selzman CH. Provider perspectives on the feasibility and utility of routine patient-reported outcomes assessment in heart failure: a qualitative analysis. *J Am Heart Assoc* 2020; 9: e013047.

121. Stehlík J, Rodriguez-Correia C, Sperutz JA, Biber J, Nativi-Nicolau J, Zickmund S, Steinberg BA, Peritz DC, Walker A, Hess J, Drakos SG, Konty AG, Fang JC, Selzman CH, Hess R. Implementation of real-time assessment of patient-reported outcomes in a heart failure clinic: a feasibility study. *J Card Fail* 2017; 23: 813–816.